Company Profile
FunPep provides the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and globally. The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer.
Its portfolio also includes FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis, FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis, and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis.
It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes. Incorporated in 2013, the company is headquartered in Ibaraki, Japan.